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Background:  Treatment  with  carvedilol  is an  established  primary  therapy  for patients  with  heart
failure  (HF).  However,  its most  common  adverse  effects,  dizziness  and  hypotension,  often  discour-
age  continuation  or dosage  increase.  The  aim  of this  study  was  to  examine  whether  switching  to
bisoprolol  from  carvedilol  would  help  to avoid  adverse  symptoms  and  signs related  to carvedilol
administration.
Methods  and  subjects:  Data were  retrospectively  collected  from  23  patients  with  HF [age  57  ±  18 years,
left  ventricular  ejection  fraction  (LVEF)  33 ± 15%] who  could  not  increase  the  dosage  of carvedilol  because
of  dizziness  or hypotension,  deﬁned  as systolic  blood  pressure  <  90 mmHg.  Before  and  immediately  after,
and 6 months  after  switching  to bisoprolol,  we  examined  symptoms,  vital  signs,  laboratory  data,  and
New  York  Heart  Association  functional  class.  Furthermore,  left  ventricular  (LV)  dimension  and  ejection
fraction  (EF)  were  evaluated  in 19  patients  using  echocardiography.
Results:  All  13 patients  with  dizziness  (100%)  and  9 of  16 with  hypotension  (56%)  were  relieved  of adverse
symptoms  or  signs.  The  mean  dose  of  carvedilol  before  switching  was  5.60  ± 3.43  mg.  Immediately  after
the switch,  the  mean  dose  of bisoprolol  was  1.84  ± 1.08  mg  and  then  increased  to  3.13  ±  1.74  mg after  6
months  (p < 0.01).  At  6-month  follow-up  examinations,  LV  function  determined  by LVEF  was  signiﬁcantly
improved,  which  was  accompanied  by increased  exercise  tolerance.
Conclusion:  Switching  from  carvedilol  to bisoprolol  may  help  with continuation  of -blocker  treatment
as  well  as  dosage  increase  in HF patients  with  adverse  symptoms  or signs,  allowing  them  to  reach  the
target  dose.
©  2013  Japanese  College  of Cardiology.  Published  by Elsevier  Ltd.  All  rights  reserved.ntroduction
Heart failure (HF) is one of the most serious causes of morbid-
ty and mortality in both developed and developing countries [1],
hile increased survival was recently demonstrated with continu-
tion of -blocker therapy in patients with chronic HF and reduced
jection fraction [2–4]. Of the various -blockers given to affected
atients, carvedilol is a multiple action non-selective -adrenergic
eceptor blocker that also induces 1-adrenergic receptor block-
de and has been shown to improve the state of HF patients in
∗ Corresponding author at: Division of Cardiovascular Medicine, Osaka University
raduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan.
el.: +81 6 6879 3640; fax: +81 6 6879 3639.
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914-5087/$ – see front matter © 2013 Japanese College of Cardiology. Published by Else
ttp://dx.doi.org/10.1016/j.jjcc.2013.01.009a number of large-scale trials [5–7]. However, the most common
adverse clinical effects of carvedilol are dizziness and hypotension
[8], and some patients are not able to continue or up-titrate the
drug because of these adverse symptoms/signs, which seem to be
mainly related to an 1 blockade effect (vasodilation). On the other
hand, bisoprolol, a highly selective 1-adrenergic receptor blocker,
has also been shown to be effective for HF patients in several studies
[9–11].
We  speculated that switching from carvedilol to bisopro-
lol would be useful for avoiding adverse symptoms/signs, and
lead to continuation or up-titration of -blocker administration
in HF patients who had adverse effects related to carvedilol
administration. In the present study, we retrospectively exam-
ined changes in symptoms, blood pressure, heart rate, New
York Heart Association (NYHA) functional class, laboratory data,
and echocardiography parameters before and after switching
to bisoprolol in patients who  showed adverse effects due to
carvedilol.
vier Ltd. All rights reserved.
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ethods
tudy patients
This retrospective study was conducted using data from a large
niversity hospital. The protocol used complies with the Decla-
ation of Helsinki and was approved by our Institutional Ethics
ommittee, which waived the need for patient consent because
f the retrospective nature of the study. Between August 2005
nd June 2011, we identiﬁed 1056 consecutive patients with
eft ventricular (LV) ejection fraction (EF) less than 50% who
ere receiving carvedilol in our hospital database. Among those,
3 in- and outpatients with chronic HF had switched medication
ecause of persistent adverse effects of carvedilol, such as dizzi-
ess and hypotension with systolic blood pressure < 90 mmHg  [12].
he diagnosis of heart failure was primarily based on signs and
ymptoms derived from a thorough history review and physical
xamination [1].
ata collection and study design
Baseline demographic information was retrospectively col-
ected from the medical records, including age, sex, height,
eight, NYHA functional class, dose of carvedilol, duration of
arvedilol therapy, underlying heart disease (ischemic or non-
schemic), comorbidities (e.g. atrial ﬁbrillation, diabetes mellitus,
hronic obstructive pulmonary disease), and medications (e.g.
ngiotensin-converting enzyme inhibitor, angiotensin-receptor
locker, calcium channel blocker, diuretic, mineralocorticoid
eceptor antagonist, digoxin, statin, pimobendan, aspirin, clopid-
grel). The following assessments were performed: evaluation of
dverse symptoms/signs, dose of -blocker, laboratory data, B-type
atriuretic peptide (BNP), echocardiographic parameters, NYHA
unctional class before the switch, and 6-month follow-up exami-
ation ﬁndings.
The effects of switching from carvedilol to bisoprolol on adverse
ymptoms/signs were evaluated immediately after the change or
t the ﬁrst follow-up visit, as well as at the 6-month follow-up
xamination. Improvement of dizziness was determined by sub-
ective reports from the patient, and relief of hypotension was
eﬁned as a blood pressure increase of more than by 10 mmHg  in
 consecutive readings obtained before and after switching medi-
ations. To investigate the effects of the switch on cardiac reverse
emodeling and symptoms, we also analyzed vital signs, echocar-
iographic and laboratory data, and NYHA functional class prior
o and immediately after switching, and at the 6-month follow-up
xamination.
nitiation of and switching from carvedilol to bisoprolol
Principally, we treat our patients using optimal medical ther-
py in line with the guidelines for management of chronic
F (http://www.j-circ.or.jp/guideline/). Treatment with carvedilol
as initiated at low doses (1.25 or 2.5 mg/day), followed by grad-
al increments (usually every 1–2 weeks) if the lower dose was
ell tolerated, during which the patient was closely monitored for
hanges in vital signs and symptoms. Planned dosage increases of
arvedilol should be delayed until side effects observed with lower
oses have disappeared. Every effort to achieve the target dose of
arvedilol (usually, 10 mg  twice daily) was made by the attending
hysician [7]. After the appearance of adverse effects, the attend-
ng physician switched from carvedilol to bisoprolol and up-titrated
he dose of bisoprolol to accomplish the target dose of 5 mg  once
aily. The tolerable maximum dosage of bisoprolol was  determined
y the physician after the switch.iology 61 (2013) 417–422
Echocardiography
Two-dimensional echo and Doppler recordings for each patient
were obtained using a commercially available echocardiographic
machine equipped with a 12-MHz transducer (Agilent Sonos 7500;
Philips Medical Systems, Andover, MA,  USA) at a standard clinical
echocardiography laboratory. The investigators were blinded to the
results of other tests and clinical examinations. LV end-diastolic
dimension (LVDd) and end-systolic dimension (LVDs) were deter-
mined from 2-D transthoracic echocardiographic images using
M-mode in parasternal long-axis views. LVEF was  calculated using
Simpson’s biplane method with apical 2- and 4-chamber views
[13].
Statistical analyses
All continuous values are expressed as the mean ± standard
deviation, and data for categorical variables are expressed as
the number and percentage of patients. All continuous vari-
ables were checked for normality using a Shapiro–Wilk test and
normal probability plot. To assess the mean differences in con-
tinuous variables between before and after switching, and at the
6-month follow-up examination, we used a Student’s paired t-
test, while a Wilcoxon signed-rank test was performed to evaluate
changes in non-normally distributed variables. The vital ﬁnd-
ings among the 3 different periods were tested using one-way
analysis of variance (ANOVA) followed by a Tukey–Kramer mul-
tiple comparison test. Differences were considered signiﬁcant at
p < 0.05. All statistical analyses were performed using commer-
cially available statistical software JMP  10.0 (SAS Institute, Cary, NC,
USA).
Results
Patient characteristics
Characteristics of the 23 patients are shown in Table 1. The
average age was 57 years and 74% were male. The majority of
patients had NYHA class III or IV heart failure symptoms, while
10 (43%) had advanced systolic HF (LVEF < 30%). Nine patients (39%)
had atrial ﬁbrillation, 5 diabetes mellitus, and 1 chronic obstruc-
tive pulmonary disease (COPD) without bronchial asthma. There
was no patient receiving both angiotensin-converting enzyme
inhibitors and angiotensin receptor blockers in a concomitant man-
ner. Fourteen patients were treated with enalapril (mean dose
2.68 ± 1.19 mg), 2 were taking candesartan (2 mg), and 1 was taking
telmisartan (20 mg).
Adverse effects of carvedilol administration
None of the 23 patients was  able to up-titrate carvedilol to
the target dose of 20 mg  because of adverse events. The rea-
sons for switching from carvedilol to bisoprolol were dizziness
in 13 patients and hypotension in 16; 6 were accompanied
by dizziness but 10 were not. The dizziness disappeared in all
13 patients after switching, while hypotension improved in 9
of 16. Moreover, there were no new reports of dizziness or
hypotension associated with bisoprolol use during the study period
(Fig. 1).
Switching from carvedilol to bisoprololThe median duration of carvedilol administration before switch-
ing was  128 days (interquartile range, 23–707 days) (Table 1).
The daily dose of carvedilol before switching was  5.60 ± 3.43 mg.
Immediately after the switch, the initial dose of bisoprolol was
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Table  1
Patient characteristics.
Variable n = 23
Age, (years) 57 ± 18
Male, n (%) 17 (74)
Body weight (kg) 56 ± 11
Body surface area (m2) 1.56 ± 0.16
Body mass index (kg/m2) 20.2 ± 3.2
New York Heart Association class, n (%)
II 11 (48)
III  10 (43)
IV  2 (9)
Duration of carvedilol therapy (days)
Median 128
Interquartile range 23–707
Daily dose of carvedilol, n (%)
<5.0 mg 8
5.0–7.4 mg 8
7.5–10.0 mg  7
>10.0 mg 0
Etiology, n (%)
Ischemic cardiomyopathy 7 (30)
Non-ischemic (systolic failure) 16 (70)
Comorbidity, n (%)
Atrial ﬁbrillation, n (%) 9 (39)
Diabetes mellitus, n (%) 5 (22)
COPD, n (%) 1 (4)
Medication at baseline, n (%)
ACE inhibitor (Enalapril), n (%) 14 (61)
Angiotensin receptor blocker, n (%) 3 (13)
Calcium channel blocker, n (%) 2 (9)
Diuretic, n (%) 17 (74)
Minaralocorticoid receptor antagonist, n (%) 17 (74)
Digoxin, n (%) 6 (23)
Statin, n (%) 4 (17)
Pimobendan, n (%) 6 (23)
Aspirin, n (%) 9 (39)
Clopidogrel, n (%) 3 (13)
Adverse symptoms/signs, n (%)
Dizziness, n (%) 13 (57)
Hypotension (<90 mm Hg), n (%) 16 (70)
Vital  signs
Blood pressure (mmHg)
Systolic 96 ± 19
Diastolic 58 ± 7
Heart rate (beats/min) 76 ± 11
Echocardiographic parameters
LV end-diastolic dimension (mm)  60.1 ± 12.9
LV  end-systolic dimension (mm)  51.1 ± 15.6
LV  ejection fraction (%) 32.7 ± 14.8
B-type natriuretic peptide (pg/ml)
Median 245
Interquartile range 111–460
Laboratory parameters
Hemoglobin (g/dl) 11.7 ± 1.8
Blood urea nitrogen (mg/dl) 23.5 ± 10.5
Serum creatinine (mg/dl) 1.11 ± 0.43
eGFR (ml/min) 59.1 ± 23.4
Serum sodium (mEq/l) 136.2 ± 3.7
Serum potassium (mEq/l) 4.3 ± 0.4
Data given as mean ± SD or the number (percentage).
COPD, chronic obstructive pulmonary disease; ACE, angiotensin-converting
e
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ness could be relieved from that adverse symptom and hypotensionnzyme; LV, left ventricular; eGFR, estimated glomerular ﬁltration rate
.84 ± 1.08 mg  and then increased to 3.13 ± 1.74 mg  after 6 months
p < 0.01). Notably, the dose of bisoprolol reached the target dose
n 9 of 23 patients (39%) at 6 months. Bisoprolol was continued in
ll of the patients and not replaced with another -blocker during
he study period.Fig. 1. Changes in dizziness and hypotension at pre-switch, and after-switch.
Changes in vital ﬁndings, and echocardiographic and laboratory
parameters after switching
Of the 23 studied patients, only 19 provided complete echocar-
diographic and laboratory data at 6 months after switching. Data for
4 who underwent 6-month follow-up examinations at the referring
hospital were not included in this analysis.
There was a signiﬁcant increase in both systolic and dia-
stolic blood pressure from before the switch to 6 months after,
whereas heart rate showed no signiﬁcant difference and plasma
BNP concentration was not signiﬁcantly improved (Table 2).
Blood pressure changed from 94.4 ± 18.7 mmHg at baseline
to 99.1 ± 17.0 mmHg  immediately after switching (p = NS) and
increased to 110.3 ± 21.2 mmHg  at 6 months (p < 0.05). In the
11 patients with dizziness, blood pressure changed from 101 ± 22
to 103 ± 20 mmHg  (p = NS) from baseline to immediately after
switch, while that change was from 85 ± 3 to 92 ± 8 mmHg
(p = 0.007) in the 14 with hypotension.
LVDd did not signiﬁcantly change and LVDs was  signiﬁcantly
decreased at 6 months after switching. As a consequence, LVEF
showed a signiﬁcant improvement, suggesting that signiﬁcant LV
reverse remodeling had occurred.
Plasma BNP concentration was  not signiﬁcantly improved, sug-
gesting that no signiﬁcant changes in cardiac wall stress occurred
after switching. As for laboratory parameters, renal function,
determined by serum creatinine level and estimated glomerular
ﬁltration rate, was  slightly decreased after switching.
Exercise tolerance
NYHA functional class was signiﬁcantly improved from before
to 6 months after switching, as the proportion of patients rated as
NYHA class I (no symptoms) or II heart failure increased, and that of
those with class III or IV heart failure decreased during the interval
from baseline to the 6-month follow-up visit (Fig. 2).
Discussion
Our results demonstrated that switching to bisoprolol from
carvedilol is useful for avoiding adverse symptoms/signs, and can
lead to continuation or up-titration of -blocker administration in
HF patients experiencing adverse effects related to carvedilol. The
major ﬁndings of the present study were (1) all patients with dizzi-was improved in more than half after switching to bisoprolol,
and (2) at 6 months after switching from carvedilol to bisoprolol,
the majority of patients showed signiﬁcant reverse LV remodeling
4 of Cardiology 61 (2013) 417–422
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nd improvement in symptoms, while no signiﬁcant reduction in
lasma BNP level occurred.
Previous US trial data have shown that dizziness accounts
or 33% and hypotension 9% of all adverse effects related to
arvedilol administration [5]. In addition, the GESICA registry
tates that hypotension is the main reason for not achieving the
arget dose of carvedilol [14]. One possible explanation for the
avorable result of switching could be differences in 1-blocking
ffect. In a previous review article, dizziness and hypotension were
ttributed to relaxation of blood vessels induced by 1 adrenocep-
or blockade [15], while the same investigator also demonstrated
hat dizziness was not related to changes in blood pressure, but
ather to central nervous system effects [16]. Of note, there were
 patients with dizziness regardless of the absence of hypotension.
ince autonomic nervous system dysfunction was not assessed, we
ere unable to deﬁnitively diagnose any of the present patients
ith autonomic dysregulation, such as orthostatic hypotension.
evertheless, our results suggest that switching from carvedilol
o bisoprolol is a practical and safe method for clinically stable
atients with LV dysfunction.
In addition, we found that the dose of bisoprolol was  sig-
iﬁcantly increased at 6 months after switching, which was
ccompanied by disappearance of carvedilol-related side-effects.
iven that the equivalent dose of bisoprolol is 1/5 that of carvedilol,
s shown in some large trials [12,17], the mean dose of carvedilol
5.60 mg)  at pre-switch was equivalent to 1.12 mg  of bisoprolol.
he patients were switched to bisoprolol at 1.84 mg  and the dose
as ﬁnally increased to 3.13 mg  during the study period, thus the
isoprolol dosage after 6 months was signiﬁcantly increased. Based
n our ﬁndings, we consider that switching from carvedilol to biso-
rolol may  also help with up-titration of the -adrenergic receptor
locker agent in such settings.
Several studies have shown that the mortality beneﬁts of
arvedilol and other -blockers are dose dependent [7,18,19]. Also,
ajor society guidelines recommend that every effort be given to
chieve the target dose of administered -blockers [1,20], although
he dose-dependent beneﬁts remain controversial [21]. It is also
mportant to exercise caution in Japan where the recommended
able 2
ital signs, laboratory data, and echocardiographic parameters.
Variables Pre-switch 
n  = 19 
Vital signs
Blood pressure (mmHg)
Systolic 94.4± 18.7 
Diastolic 58.6 ± 5.5 
Heart rate (beats/min) 76 ± 12 
Echocardiographic parameters, n (%)
LV  end-diastolic dimension (mm)  61.1± 13.7 
LV  end-systolic dimension (mm)  52.6± 15.8 
LV  ejection fraction (%) 30.7± 13.5 
B-type  natriuretic peptide (pg/ml)
Median 223 
Interquartile range 114–458 
Laboratory parameters, n (%)
Hemoglobin (g/dl) 11.6 ± 1.8 
Blood  urea nitrogen (mg/dl) 23.8 ± 8.7 
Serum  creatinine (mg/dl) 1.1 ± 0.5 
eGFR  (mL/min per 1.73 m2) 59.9 ± 25.4 
Serum  sodium (mEq/l) 137 ± 3 
Serum  potassium (mEq/l) 4.3 ± 0.5 
ata given as mean ± SD or the number (percentage).
V, left ventricular; eGFR, estimated glomerular ﬁltration rate.
* Tested with Wilcoxon signed-rank method.
† Tested with one-way analysis of variant (ANOVA).
‡ >Pre-switch, Tukey–Kramer test P < 0.05.
§ >After-switch, Tukey–Kramer test P < 0.05.Fig. 2. Effects of switching from carvedilol to bisoprolol on New York Heart Associ-
ation (NYHA) functional class.
maximum doses of -blockers are less than half of those in West-
ern countries, while there is limited evidence of the tolerability of
daily carvedilol doses higher than 20 mg  in Japanese chronic HF
patients. In our study, LVEF and NYHA functional class were sig-
niﬁcantly improved after switching from carvedilol to bisoprolol.
It is well known that -blocker administration reduces LV volume
along with improvement in systolic function, leading to improve-
ment in prognosis [22], which also occurs in a dose-dependent
manner [7]. Therefore, switching from carvedilol to bisoprolol may
provide beneﬁcial effects in regard to prognosis and/or reverse
remodeling in patients who  experience difﬁculty with continua-
tion or up-titration of carvedilol because of adverse effects such as
dizziness or hypotension.
Despite LV reverse remodeling and improvement in NYHA class,
there was  no signiﬁcant change in BNP level. BNP is a hormone
of cardiac origin that is secreted speciﬁcally from the ventricle in
response to volume expansion and pressure overload [23], as well
as abnormal constructive change such as hypertrophy and/or ﬁbro-
sis. Our data suggest that the improvements in functional class and
After-switch 6 months P-Value
n = 19 n = 19
99.1 ± 17.0 110.3 ± 21.2‡ <0.05†
55.6 ± 7.8 63.5 ± 10.3§ <0.05†
74 ± 13 74 ± 12 NS
n.a. 59.3 ± 14.4 NS
n.a. 47.6 ± 16.8 p < 0.01
n.a. 39.9 ± 13.8 p < 0.001
n.a. 194 NS*
n.a. 86–331
n.a. 12.0 ± 1.6 NS
n.a. 27.2 ± 11.6 p = 0.054
n.a. 1.2 ± 0.5 <0.01
n.a. 53.9 ± 18.5 <0.05
n.a. 138 ± 4 NS
n.a. 4.5 ± 0.4 NS
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V reverse remodeling after switching may  be mainly mediated by
eurohormonal modulations of the adrenergic receptor blockers
hemselves, rather than by a reduction in circulating plasma/blood
olume and subsequent decreased wall stress, or decreased pres-
ure overload.
Although a favorable effect of switching to bisoprolol was shown
n patients with adverse effects due to carvedilol administration
n our study, there were two unexpected results. First, heart rate
as not signiﬁcantly changed, although there was improvement
n blood pressure after switching to and increasing the dose of
isoprolol, which might have been due to the highly selected popu-
ation with hypotension in our study. It is also conceivable that our
tudy patients had already taken carvedilol before switching, thus
o heart rate reduction could be achieved with an increase in dose.
econd, there was signiﬁcant exacerbation of renal function found
n the present subjects, which was recently reported to be a strong
redictor of prognosis in patients with HF [24]. It is also well known
hat renal function is progressively worsened in HF patients. Kon-
shi et al. reported that there was no difference regarding impact on
enal function between carvedilol and bisoprolol [25], while wors-
ning renal function was  attributed to use of diuretics in that study.
n the other hand, it has been reported to be important whether
he pharmacological intervention improves clinical outcomes even
n such HF patients [26]. As there was no control group without
-blocker administration in the present study, we cannot con-
lude whether the change in estimated glomerular ﬁltration rate
uring 6 months could be attributed to the switch of carvedilol to
isoprolol, other drugs (diuretics, etc.), or the natural course of HF.
dditional well-designed prospective large-scale investigations
re needed to more closely examine the efﬁcacy of this switching
trategy.
tudy limitations
The main limitations of the present study are the small num-
er of enrolled patients and absence of a control group. Moreover,
lthough clinical data obtained at 6 months after switching are
onsidered to be integral to understand the immediate effect of
he -blocker itself and LV reverse remodeling, we were unable
o assess laboratory and echocardiographic data immediately after
he switch. Therefore, it is not possible to deﬁnitively conclude
rom our ﬁndings that switching from carvedilol to bisoprolol will
roduce favorable effects in patients with chronic HF in all sett-
ngs. It is well known that systolic blood pressure increases later
n HF patients with hypotension who respond to -blockers [27],
hus the clinical implications of our observations are also limited.
evertheless, our retrospective series consisted of consecutive
atients with impediments caused by carvedilol administration
n actual clinical settings, thus the results may  provide help-
ul insight for determining effective -blockade strategies for HF
atients.
onclusion
Switching from carvedilol to bisoprolol may  help with continu-
tion of -blocker treatment as well as dosage increase in patients
ith adverse symptoms or signs, allowing them to reach the target
ose.
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